MedTrace Logo

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2014-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Dexamethasone 0.1% ophthalmic suspension

Maxidex

DRUG

Olopatadine hydrochloride 0.1% ophthalmic solution

Patanol

OTHER

Inactive ingredients, used as placebo

Tears Naturale II

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119287 on ClinicalTrials.gov